Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.
Filter by
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product.
Purbhoo, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models.
Yigit, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Identification and characterization of an allogeneic iNKT-CAR targeting BCMA.
Michelet, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results.
El-Khoueiry, et al.
MK-4830 (ILT4 Antagonist)
Clinical Cancer Research
Oct 1, 2021
First-in-Class Anti-immunoglobulin – like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.